United Kingdom Glp-1 Receptor Agonist Market Insight
The United KingdomGlp-1 Receptor Agonist Market is growing at an 12.95%CAGR, driven by rising obesity and diabetes, increasing weight management demand, and NHS adoption of semaglutide and liraglutide therapies.
United KingdomGlp-1 Receptor Agonist Market Insights Forecasts to 2035
- The United KingdomGlp-1 Receptor Agonist Market Size Was Estimated at USD 1281.2Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.95% from 2025 to 2035
- The United KingdomGlp-1 Receptor Agonist Market Size is Expected to Reach USD 4328.4Million by 2035
Notable Insightsfor United KingdomGlp-1 Receptor Agonist Market
- By drug type, semaglutide-based therapies dominate the UK GLP-1 market, holding approximately 48–50% share in 2024 prescriptions, driven by superior weight loss efficacy and strong glycaemia control compared to other GLP-1 drugs.
- Byapplication, type 2 diabetes accounts for around 60–65% of total GLP-1 use in the UK, followed by obesity management, with overall GLP-1 prescriptions growing nearly 18% annually between 2021 and 2024.
- Demand for obesity treatment has surged significantly in the UK, with nearly 4.9 million adults using or seeking GLP-1 therapies, reflecting rising BMI-related comorbidities and increased awareness of metabolic health risks nationwide.
- Long-acting injectable GLP-1 formulations dominate patient preference, contributing to over 70% of new initiations in NHS settings, as once-weekly dosing improves adherence, convenience, and long-term treatment effectiveness compared to daily therapies.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Glp-1 Receptor Agonist Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Glp-1 Receptor Agonist Market
- Novo Nordisk
- EliLilly and Company
- AstraZeneca
- Sanofi
- Pfizer
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck & Co.
- Others
Recent Developments:
- In June 2025, Mounjaro (tirzepatide) NHS rollout: Eli Lilly’s dual GLP-1/GIP receptor agonist began phased UK access for severe obesity patients with comorbidities, expanding advanced weight management treatment options.
- In September 2024, Wegovy (semaglutide) expansion: A Scotland NHS-backed study is providing 3,000–5,000 patients in deprived areas access to GLP-1 therapy, assessing real-world obesity treatment outcomes and health equity impact.
Market Segmentation:
United Kingdom Glp-1 Receptor Agonist Market, By Drug Class
- Semaglutide
- Liraglutide
- Dulaglutide
- Exenatide
- Others
United Kingdom Glp-1 Receptor Agonist Market, By Route of Administration
- Oral
- Injectable
United KingdomGlp-1 Receptor Agonist Market, By Application
- Type 2 Diabetes
- Obesity Management
- Cardiovascular Risk Reduction
- Others
United Kingdom Glp-1 Receptor Agonist Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK GLP-1 receptor agonist market is expected to expand significantly due to rising metabolic disease burden and increasing acceptance of pharmacological weight management therapies. Experts highlight semaglutide and emerging dual agonists as key growth drivers, with NHS-backed obesity treatment programs accelerating long-term demand. Future innovations in oral GLP-1 formulations and combination therapies are expected to further transform diabetes and obesity care pathways in the UK through 2035.